Menu

Blog

Archive for the ‘biotech/medical’ category: Page 1819

Dec 2, 2019

Cross-linking of the Extracellular Matrix — Dr. William Bains

Posted by in categories: biotech/medical, life extension

The University of Cambridge’s Dr. William Bains provides a thorough overview of extracellular cross-links in this lecture. He explains that advanced glycation end-products (AGEs) can irreversibly link proteins together, and cross-linking AGEs appear to play an important role in aging. They are particularly problematic in the cardiovascular system, where cross-links cause our arteries to stiffen with age, raising blood pressure and making a patient more likely to suffer from a heart attack or stroke. Cross-links are also implicated in complications from diabetes. Dr. Bains explains the structure and nature of cross-links, where they accumulate in the body, and even what their surprising role is in cooking. He ends by discussing a major AGE-breaking drug that has been tested on humans and touches on potential future therapies.

Visit www.sens.org/videos to view the rest of our course lecture videos.

Dec 2, 2019

How Joe Tippens Beat Terminal Cancer with $7 Dog Medicine — Interviewed by James Templeton

Posted by in categories: biotech/medical, health

https://www.youtube.com/watch?v=fCOODjrJhRQ&feature=share

Diagnosed with terminal lung cancer, Joe was told he had about 3 months to live. A veterinarian friend of his in western Oklahoma called him and told him about a cancer research experiment he had learned about in which a dog-deworming medicine had cured cancer in the experimental mice… and when the researcher developed cancer, she used the same medicine on herself and her glioblastoma was gone in about 12 weeks.

With nothing to lose and everything to gain, Joe ordered the veterinary product, Fenbendazole, and began taking it. He added a few other things to his regimen such as curcumin and Vitamin E, now known as the “Joe Tippens Protocol”. Three and a half months later, he went in for a scan and he was totally clear!

Continue reading “How Joe Tippens Beat Terminal Cancer with $7 Dog Medicine — Interviewed by James Templeton” »

Dec 2, 2019

We are going to live longer; prepare now

Posted by in categories: biotech/medical, economics, life extension

Understanding the economic implications of changing demographics is essential for investors, said Aubrey de Grey, a biomedical gerontologist speaking at the Fiduciary Investors’ Symposium at Harvard University. De Grey, who is also the chief science officer of SENS Research Foundation, a California-based biomedical research charity, warned gathered delegates that they need to urgently position for people living much longer.

“The implications will change your outlook on the future. You need to understand and believe the actual logic of what is coming,” he said.

He noted that medical advancement has eliminated many of the problems that used to kill people when they were young. For example, better hygiene saves lives the world over. In contrast, health problems in later life are still killing many of us in an enduring ageing process. Simply defined, this sees our metabolism generate damage over the years that cause accumulative changes over time. We can only tolerate so much change; inevitably we go down hill until we die, he said. Today the majority of medical effort is concentrated on geriatric medicine and managing the consequences of this ageing process. Yet attacking the consequences of something that is accumulating is the wrong way to approach the problem.

Dec 1, 2019

$5m project to begin building NZ’s first ‘gene bank’

Posted by in category: biotech/medical

Scientists aim to tackle diseases hurting Kiwis by building NZ’s first genomic database.

Dec 1, 2019

With Ancient Human DNA, Africa’s Deep History Is Coming to Light

Posted by in category: biotech/medical

Want it all? Get unlimited access when you subscribe.

Nov 30, 2019

Red Wine Antioxidant Kills Cancer

Posted by in categories: biotech/medical, food

Red wine has been known to be healthy for many reasons, but some recent studies show that antioxidants in red wine can actually kill cancer.

Not only is it helpful in preventing cancer, but it can also help to fight it once it has been detected.

Cancer is a life-threatening disease that can kill people of any age.

Nov 30, 2019

Scientists Get the Green Light to Create Human-Animal Hybrids in Japan

Posted by in categories: bioengineering, biotech/medical, ethics, government, life extension

Human-animal hybrids are set to be developed at the University of Tokyo after the Japanese government recently lifted a ban on the controversial stem-cell research.

Hiromitsu Nakauchi—director for Stem Cell Biology and Regenerative Medicine at the University of Tokyo and team leader at Stanford’s Nakauchi Lab—is the first to receive approval for the questionable experiments which will attempt to grow human cells in rat and mouse embryos before being brought to term in a surrogate animal.

Despite many feeling that such studies are the equivalent of playing God, scientists say that the objective is far from sinister. It’s theorized that developing animals with organs constructed from human cells will create organs that can then be used for transplants in humans, cutting the long organ donation waitlists.

Nov 30, 2019

How to Live Forever with Dr. Aubrey de Grey

Posted by in categories: biotech/medical, life extension

This episode will take you through Dr. Aubrey de Grey’s Seven Pillars of aging, the research that he’s currently doing, his opinion on biological age, AGEs and the different sources, and the impact of growth hormone on biological age.

Who is Dr. Aubrey de Grey?

Continue reading “How to Live Forever with Dr. Aubrey de Grey” »

Nov 30, 2019

Gut microbiome fermentation determines of the efficacy of exercise for prediabetics

Posted by in categories: biotech/medical, health

A team of researchers affiliated with multiple institutions in China has found that the makeup of the gut microbiome can be a determiner for the efficacy of exercise with prediabetics. In their paper published in the journal Cell Metabolism, the group describes their study of prediabetic volunteers and exercise and what they found.

In the , type 2 diabetes is considered to be preventable in most people—all it takes is a change in diet and an increase in . But things may not be as simple as that as the researchers with this new effort discovered—they found that exercise does not always lead to reductions in .

The study by the team involved asking 29 male prediabetic volunteers to undergo glucose and gut microbe testing. Then the group was divided into two—20 volunteers were asked to undergo an exercise regimen for three months while the other 19 were asked to maintain their normal eating and exercise habits. At the end of the three-month period, all of the volunteers once again underwent glucose and gut microbe metabolic testing.

Nov 30, 2019

CRISPR-Switch regulates sgRNA activity

Posted by in categories: bioengineering, biotech/medical

CRISPR-Cas9 is an efficient and versatile tool for genome engineering in many species. However, inducible CRISPR-Cas9 editing systems that regulate Cas9 activity or sgRNA expression often suffer from significant limitations, including reduced editing capacity, off-target effects, or leaky expression. Here, we develop a precisely controlled sgRNA expression cassette that can be combined with widely-used Cre systems, termed CRISPR-Switch (SgRNA With Induction/Termination by Cre Homologous recombination). Switch-ON facilitates controlled, rapid induction of sgRNA activity. In turn, Switch-OFF-mediated termination of editing improves generation of heterozygous genotypes and can limit off-target effects. Furthermore, we design sequential CRISPR-Switch-based editing of two loci in a strictly programmable manner and determined the order of mutagenic events that leads to development of glioblastoma in mice. Thus, CRISPR-Switch substantially increases the versatility of gene editing through precise and rapid switching ON or OFF sgRNA activity, as well as switching OVER to secondary sgRNAs.